<DOC>
	<DOCNO>NCT00079911</DOCNO>
	<brief_summary>This clinical research study international trial evaluate safety effectiveness market drug compare placebo ( like sugar pill ) suppression repeat genital herpes infection HIV-infected subject CD4+ count &lt; 100 cells/mm3 .</brief_summary>
	<brief_title>A Clinical Research Study For The Suppression And Treatment Of Genital Herpes Infection In HIV-Infected Persons</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Herpes Genitalis</mesh_term>
	<mesh_term>Valacyclovir</mesh_term>
	<mesh_term>Acyclovir</mesh_term>
	<criteria>CD4+ lymphocyte count &lt; 100cells/mm3 screen visit . Documented history HIV infection Must receive stable , combination anti HIV drug least 4 month immediately prior participation , per investigator , unlikely require change antiHIV drug sixmonth study . Laboratory confirmation genital herpes ( positive Herpes Simplex Virus2 antibody test ) . 3 outbreaks genital herpes previous 12 month genital herpes medicine currently . 3 outbreaks genital herpes per year period prior begin treatment chronic genital herpes . Kidney diseases . Liver diseases . Known allergic reaction VALTREX ( valaciclovir ) , ZOVIRAX ( acyclovir ) , FAMVIR ( famciclovir ) , CYTOVENE ( ganciclovir ) . Vomiting syndrome . Must willing discontinue take current genital herpes medicine 1 week prior participation . Active AIDSindicator condition , define CDC Category C. Other protocol inclusion exclusion criterion evaluate research physician .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Herpes</keyword>
	<keyword>Genital Herpes</keyword>
	<keyword>HIV</keyword>
	<keyword>HSV</keyword>
</DOC>